DPP4 and metabolic dysfunction-associated steatotic liver disease: Interestingly, there are currently clinical trials evaluating the efficacy and safety of DPP4 inhibitor sitagliptin for the treatment of NAFLD (Fukuhara et al, 2014) and in steatosis irrespective of diabetes in NASH (Alam et al, 2018).